WO2001007576A2 - Intramolecularly cross-linked subtilisin proteases having reduced immunogenicity - Google Patents
Intramolecularly cross-linked subtilisin proteases having reduced immunogenicity Download PDFInfo
- Publication number
- WO2001007576A2 WO2001007576A2 PCT/US2000/018853 US0018853W WO0107576A2 WO 2001007576 A2 WO2001007576 A2 WO 2001007576A2 US 0018853 W US0018853 W US 0018853W WO 0107576 A2 WO0107576 A2 WO 0107576A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protease
- region
- residue
- positions
- epitope region
- Prior art date
Links
- 0 *CC(Nc(cc1)ccc1C(ON(C(CC1)=O)C1=O)=O)=O Chemical compound *CC(Nc(cc1)ccc1C(ON(C(CC1)=O)C1=O)=O)=O 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
- C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
Definitions
- the present invention relates to modified subti sin proteases which are useful in compositions such as, for example, personal care compositions, laundry compositions, hard surface cleansing compositions, and light duty cleaning compositions.
- Enzymes make up the largest class of naturally occurring proteins.
- One class of enzyme includes proteases which catalyze the hydrolysis of other proteins This ability to hydrolyze proteins has typically been exploited by incorporating naturally occurring and geneticalK engineered proteases into cleaning compositions, particularly those relevant to laundry applications.
- proteases In the cleaning arts, the mostly widely utilized of these proteases are the serme proteases. Most of these se ⁇ ne proteases are produced by bacterial organisms while some are produced by other organisms, such as fungi. See Siezen et al., "Homology Modelling and Protein Engineering Strategy of Subtilases, the Family of Subtihsin-Like Se ⁇ ne Proteases", Protein Engineering, Vol 4, No 7, pp 719 - 737 (1991).
- protease characte ⁇ stics such as, for example, thermal stability, pH stability, oxidative stability, and substrate specificity are not necessarily optimized for utilization outside the natural environment of the protease
- proteases have not been commercially utilized in personal care compositions and light duty detergents.
- a pnmary reason for the absence of these proteases in products such as, for example, soaps, gels, body washes, shampoos, and light duty dish detergents is due to the problem of human sensitization leading to undesirable immunogenic responses. It would therefore be highly advantageous to provide a personal care composition or a light duty detergent which provides the cleansing properties of proteases without the provocation of an immunogenic response.
- immunogenic response to proteases may be minimized by immobilizing, granulating, coating, or dissolving chemically modified proteases to avoid their becoming airborne. These methods, while addressing consumer exposure to airborne proteases, still present the nsks associated with extended tissue contact with the finished composition.
- the present inventors have surpnsmgly discovered that by mtramolecularly cross-linking the protease, the lmmunogemcity of the protease is reduced. It has further been discovered that these mtramolecularly cross-linked proteases maintain the activity of the respective parent protease. In addition, the present inventors have discovered defined residues withm the protease which are most preferable to participate in cross-linking due to, for example, stenc location to the epitope regions (i e , locations of the protease which are responsible for the immune response) or clip sites (i.e., locations of the protease where hydrolysis occurs in vivo) of the protease.
- the present inventors have therefore discovered subtihsm proteases which evoke a decreased immunogenic response yet maintain their activity as an efficient and active protease. Accordingly, the present proteases are suitable for use in several types of compositions including, but not limited to, laundry, dish, hard surface, skin care, hair care, beauty care, oral care, and contact lens compositions.
- the present invention is directed to subtihsm proteases compnsmg an intramolecular cross-l k, wherein the intramolecular cross-lmk comp ⁇ ses a covalent linkage between an ammo acid of a first residue of the protease and an amino acid of a second residue of the protease.
- proteases of the present mvention have decreased lmmunogemcity relative to the parent protease. Accordingly, such proteases are suitable for use m several types of compositions including, but not limited to, laundry, dish, hard surface, skm care, hair care, beauty care, oral care, and contact lens compositions.
- the present invention can compnse, consist of, or consist essentially of any of the required or optional components and / or limitations descnbed herein.
- matenals including, but not limited to, enzymes
- the inventors herein do not intend to be limited by matenals under a certain trade name Equivalent mate ⁇ als (e.g., those obtained from a different source under a different name or catalog (reference) number) to those referenced by trade name may be substituted and utilized for the proteases and compositions herein.
- mutation refers to an alteration in a gene sequence and / or an ammo acid sequence produced by those gene sequences. Mutations include deletions, substitutions, and additions of ammo acid residues to the wild-type protein sequence.
- parent refers to a protein (wild-type or vanant) which is utilized for further modification to form a protease conjugate herein.
- wild-type refers to a protein, for example a protease or other enzyme, produced by unmutated organisms.
- vanant means a protein having an ammo acid sequence which differs from that of the corresponding wild-type protein.
- mtramolecularly cross-linked proteases of the present invention are not limited to those comprising subtihsm BPN' and vanants thereof, all ammo acid numbenng is with reference to the amino acid sequence for subtihsm BPN' which is represented by SEQ ID NO: l.
- the ammo acid sequence for subtihsm BPN' is further descnbed by Wells et al, Nucleic Acids Research, Vol. II, pp. 7911 - 7925 (1983).
- a hyphen is utilized to define a region of ammo acid residues, it is intended that this region is inclusive of the listed residues and each residue occur ⁇ ng between the listed residues.
- this is intended to convey the region of ammo acid residues 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, and 84.
- the present invention is directed to subtihsm proteases compnsmg an intramolecular cross-lmk, wherein the intramolecular cross-lmk comp ⁇ ses a covalent linkage between an amino acid of a first residue of the protease and an ammo acid of a second residue of the protease.
- the resulting cross-lmk decreases the rate of protease degradation in the endosomal compartments of the antigen presenting cells (i.e , increases stability) which, in turn, impedes presentation of the epitopes of the protease.
- proteases which may be mtramolecularly cross-linked according to the present invention are subtilism-hke proteases, either wild-type or va ⁇ ants thereof.
- subtilism-hke proteases either wild-type or va ⁇ ants thereof.
- subtilism-hke proteases as used herein, the term "subtihsin-like protease” means a protease which has at least 50%, and preferably 80%, ammo acid sequence identity with the sequences of subtihsm BPN'. Wild-type subtihsin-like proteases are produced by, for example, Bacillus alcaloph ⁇ us , Bacillus amylohquefaciens .
- Preferred proteases which may be mtramolecularly cross-linked in accordance with the present invention include, for example, those obtained from Bacillus amylohquefaciens, Bacillus hcheniformis, and Bacillus subtihs, subtihsm BPN, subtihsm BPN', subtihsm Carlsberg. subtihsm DY, subtihsm 309, protemase K, and thermitase, including A/S Alcalase®
- the most preferred proteases herein are subtihsm BPN' and va ⁇ ants thereof.
- Protease A for use herein are disclosed in U.S. Patent No 5,030,378, Venegas. issued July 9, 1991, as characterized by the subtihsm BPN' ammo acid sequence with the following mutations-
- Gly at position 166 is substituted with an ammo acid residue selected from Asn, Ser, Lys, Arg, His, Gin, Ala and Glu
- Gly at position 169 is substituted with Ser
- Met at position 222 is substituted with an ammo acid residue selected from Gin, Phe, His, Asn, Glu, Ala and Thr; or
- Protease B for use in intramolecular cross-lmkmg herein are disclosed in EP 251 ,446, assigned to Genencor International, Inc., published January 7, 1988, as characterized by the wild-type subtihsm BPN' ammo acid sequence with mutations at one or more of the following positions: Tyr21, Thr22, Ser24, Asp36, Ala45, Ala48, Ser49, Met50, H ⁇ s67, Ser87, Lys94, Val95, Gly97, SerlOl, Gly 102, Gly 103, Ilel07, Gly 110, Met 124, Glyl27, Glyl28, Prol29, Leul35, Lysl70, Tyrl71, Prol72, Aspl97, Metl99, Ser204, Lys213, Tyr214, Gly215, and Ser221 ; or two or more of the positions listed above combined with one or more mutations at
- Protease C preferred subtihsm BPN' variants for use m intramolecular cross-lmkmg herein are hereinafter referred to as "Protease C", and are descnbed in WO 95/10615, assigned to Genencor International Inc., published April 20, 1995, as characterized by the wild-type subtihsm BPN' ammo acid sequence with a mutation to position Asn76, in combination with mutations in one or more other positions selected from Asp99, SerlOl, Glnl03, Tyrl04, Serl05, Ilel07, Asnl09, Asnl23, Leul26, Glyl27, Glyl28, Leul35, Glul56, Glyl66, Glul95, Aspl97, Ser204, Gln206, Pro210, Ala216, Tyr217, Asn218, Met222, Ser260, Lys265, and Ala274.
- Protease D preferred subtihsm BPN' variants for use in intramolecular cross-lmkmg herein, hereinafter referred to as "Protease D" are descnbed in U.S. Patent No. 4,760,025, Estell et al., issued July 26, 1988, as characterized by the wild-type subtihsm BPN' ammo acid sequence with mutations to one or more ammo acid positions selected from the group consisting of Asp32, Ser33, H ⁇ s64, Tyrl04, Asnl55, Glul56, Gly 166, Glyl69, Phel89, Tyr217, and Met222.
- proteases which may be mtramolecularly cross-linked herein are selected from the group consisting of subtihsm BPN', Protease A, Protease B, Protease C, and Protease D, with Protease D being the most preferred.
- the mtramolecularly cross-linked proteases of the present invention comp ⁇ se a covalent linkage between two ammo acids of a foregoing protease. These ammo acids are referred to independently herein as the ammo acid of a first residue and the amino acid of a second residue.
- first residue and second residue should not be construed as refer ⁇ ng to position 1 and position 2, respectively, corresponding to subtihsm BPN'. Rather, these terms are used simply to cla ⁇ fy references to one residue or the other.
- the first residue may correspond to position 27 of subtihsm BPN' and the second residue may correspond to position 118 of subtihsm BPN'.
- the first residue corresponds to position 1 of subtihsm BPN' or that the second residue corresponds to position 2 of subtihsm BPN'.
- cysteme (which does not naturally occur in subtihsm BPN') is a highly preferred ammo acid residue of the first residue or the second residue.
- the intramolecular cross-lmk of the subtihsm protease comprises a covalent linkage between an ammo acid of a first residue of the protease and an ammo acid of a second residue of the protease.
- Such covalent linkage comp ⁇ ses a linking moiety which bridges the first residue and the second residue.
- the linking moiety may be any structural mechanism through which the first residue and the second residue may be covalently bndged (attached).
- the linking moiety is not simply a covalent bond such as that which forms, for example, a mere disulfide b ⁇ dge. Without intending to be limited by theory, the present inventors have discovered that such disulfide b ⁇ dges are ineffective m providing an mtramolecularly cross-linked protease having decreased lmmunogemcity relative to the parent
- the linking moiety may be any small molecule, i e , a molecule having a molecular weight of less than about 1600, preferably less than about 800, more preferably less than about 400, and most preferably less than about 300.
- the most preferred linking moieties include those capable of being covalently bound to one or more cysteme residues, lysine residues, and / or the ammo terminus of the protease.
- the ammo acid of the first residue compnses an amme group (e.g , as non-limiting examples, the ammo acid of the first residue is lysine (either through natural occurrence or mutation) or the ammo acid of the first residue is the ammo terminus of the protease)
- the ammo acid of the second residue comprises a thiol group, e g , as a non-limiting example, the ammo acid of the second residue is cysteme (either through natural occurrence or mutation).
- non-hmitmg reagents may be utilized to form the covalent linkage of the mtramolecularly cross-linked proteases of the present invention: N-[alpha- male ⁇ m ⁇ doacetoxy]succm ⁇ m ⁇ de ester; N-5-az ⁇ do-2-n ⁇ trobenzoyloxysuccm ⁇ m ⁇ de; bismaleimidohexane; N-[beta-male ⁇ midopropyloxy]succm ⁇ m ⁇ de ester; b ⁇ s[2-
- linking moieties and related chemistry are disclosed in U.S. Patent No 5,446,090. Hams, issued August 29, 1995; U.S. Patent No. 5,171,264, Mer ⁇ ll, issued December 15, 1992; U.S. Patent No. 5,162,430, Rhee et al.. issued November 10, 1992; U.S. Patent No. 5,153,265, Shadle et al. issued October 6, 1992; U.S. Patent No. 5,122,614, Zahpskv, issued June 16, 1992; Goodson et al., "Site-Directed Pegylation of Recombinant Interleukm-2 at its Glycosylation Site", Biotechnology, Vol. 8, No. 4, pp.
- the ammo acid of the first residue compnses an amine group (e.g., as non-hmiting examples, the ammo acid of the first residue is lysine (either through natural occurrence or mutation) or the ammo acid of the first residue compnses the amino terminus of the protease). It is therefore preferred to mutate lysine residues which occur at positions other than the first and second residues to one or more other ammo acid residues such that cross-lmkmg of a lysine residue at, e.g. , the first residue, is selective.
- a lysine residue occurs at position 43 of subtihsm BPN' which is in the first proximal epitope region as defined herein.
- Site-selective mutation of all other lysme residues occurnng m the protease may be performed followed by selective cross-lmkmg of the lysine residue at position 43 to the second residue.
- a naturally occurring amino acid of the first residue may be mutated to lysine (for example), followed by site-selective mutation of all other lysine residues occurnng in the protease, and selective cross-lmkmg of the lysine residue to the second residue.
- the ammo acid of the second residue comp ⁇ ses a thiol group, e g., as a non-hmitmg example, the ammo acid of the second residue is cysteme (either through natural occurrence or mutation).
- cysteme either through natural occurrence or mutation.
- the ammo acid of the first and second residues each comprise a thiol group.
- the ammo acid of the first residue is cysteme (either through natural occurrence or mutation) and the ammo acid of the second residue is cysteme (either through natural occurrence or mutation).
- cysteme residue occurs at a position other than the first and second residues, it is preferable to substitute another ammo acid residue for cysteme in each of those positions to enable selective cross-lmkmg between the first residue and the second residue.
- the ammo acid of the first and second residues each comprise an amine group.
- the ammo acid of the first residue may be lysine or the ammo terminus (either through natural occurrence or mutation) and the ammo acid of the second residue is lysine (either through natural occurrence or mutation).
- lysine occurs at a position other than the first and second residues, it is preferable to substitute another ammo acid residue for lysine in each of those positions to enable selective cross-linking between the first residue and the second residue.
- the ammo acid of the first residue is lysine or comprises the ammo terminus and the ammo acid of the second residue is cysteme.
- the amino acid of the first residue is cysteme and the ammo acid of the second residue is cysteme.
- the ammo acid of the first residue is lysme or the ammo terminus and the ammo acid of the second residue is lysme.
- At least one of the first and second residues occur withm a defined region. It has been discovered that the subtihsm protease comp ⁇ ses three epitope regions Accordingly, without intending to be limited by theory, it is believed that wherein a residue of one or more of these epitope regions participates in cross- lmkmg, lmmunogemcity is reduced because presentation of the epitope is impeded For example, wherein a residue of one or more of the epitope regions is cross-linked to another residue of the protease, multiple cleavages of the protease will be required p ⁇ or to presentation of the epitope.
- the first epitope region corresponds to positions 70 - 84 of subtihsm BPN'; the second epitope region corresponds to positions 103 - 126 of subtihsm BPN'; and the third epitope region corresponds to positions 220 - 246 of subtihsm BPN'.
- residues of the protease are m close proximity to the epitope regions of the protease.
- the present inventors have discovered that residues of the first, second, and third proximal epitope regions are in close proximity to the first, second, and third epitope regions, respectively. Accordingly, without intending to be limited by theory, it is believed that wherein a residue of one or more of a first, second, or third proximal epitope region participates in cross-linking, lmmunogenicity is reduced because presentation of the epitope is impeded.
- the first proximal epitope region corresponds to positions 2, 3, 4, 5, 6, 7, 12, 17, 36, 40, 41, 43, 44, 45, 67, 86, 87, 89, 206, 209, 210, 212, 213, 214, 215, and 216 of subtihsm BPN';
- the second proximal epitope region corresponds to positions 25, 26, 27, 46, 47, 48, 49, 50, 51, 52, 53, 54, 91, 99, 100, 101, 102, 127, 128, 129, 130, 131, 132, 133, 134, 136, 137, 138, 140, 141, 144, and 145 of subtihsm BPN';
- the third proximal epitope region corresponds to positions 9, 10, 22, 23, 24, 62, 63, 143, 146, 154, 155, 156, 157, 172, 173, 187, 189, 195, 197, 203, 204, 253, 254,
- the subtihsm protease comp ⁇ ses a first "clip site” region and a second "clip site” region (i e , locations of the protease where hydrolysis occurs in vivo). Without intending to be limited by theory, it is believed that wherein one or more residues m these clip site regions participates in cross-lmkmg, hydrolysis of the protease is impeded and thus presentation of an epitope is similarly impeded.
- the first clip site region corresponds to positions 156 - 165, 170, 186, 191 - 196, and 259 - 262 of subtihsm BPN' and the second clip site region corresponds to positions 12 - 24, 27, 84 - 88, 271, and 274 of subtihsm BPN' See, e.g , U.S Provisional Patent Application Serial No. 60/144,981, Weisgerber et al., "Protease Conjugates Having Stencally Protected Clip Sites", filed July 22, 1999.
- the present protease comp ⁇ ses an intramolecular cross-link, wherein the intramolecular cross-lmk compnses a covalent linkage between an ammo acid of a first residue of the protease and an amino acid residue of a second residue of the protease, wherein at least one of the residues occurs withm a region selected from'
- subtihsm BPN' 134, 136, 137, 138, 140, 141, 144, and 145 of subtihsm BPN', and (i) a third proximal epitope region corresponding to positions 9, 10, 22, 23, 24, 62, 63, 143, 146, 154, 155, 156, 157, 172, 173, 187, 189, 195, 197, 203, 204, 253, 254, 256, 265, 267, 269, 271, 272, and 275 of subtihsm BPN'.
- the other residue is selected from any other position of the protease.
- At least one of the residues occurs withm a region selected from the ammo terminus region, the first epitope region, the second epitope region, the third epitope region, the first clip site region, and the second clip site region. More preferably, at least one of the residues occurs withm a region selected from the ammo terminus region, the first epitope region, the second epitope region, and the third epitope region. Even more preferably, at least one of the residues occurs withm a region selected from the first epitope region, the second epitope region, and the third epitope region. Most preferably, at least one of the residues occurs within the first epitope region.
- each of the first and second residues of the protease occur withm a region selected from the ammo terminus region, the first epitope region, the second epitope region, the third epitope region, the first clip site region, the second clip site region, the first proximal epitope region, the second proximal epitope region, and the third proximal epitope region.
- the first residue corresponds to position 1 of subtihsm BPN' and the second residue occurs withm a region selected from the group consisting of the first epitope region, the second epitope region, the third epitope region, the first clip site region, the second clip site region, the first proximal epitope region, the second proximal epitope region, and the third proximal epitope region
- the region preferably corresponds to positions 75 - 83 of subtihsm BPN'. More preferably, the region corresponds to position 78 of subtihsm BPN'.
- the region preferably corresponds to positions 109, 114, and 118 of subtihsm BPN'. most preferably 118.
- the region preferably corresponds to position 240 of subtihsm BPN'
- the region preferably corresponds to positions 158, 159, 160, 161, 162, 163, 164, 165, 170, 186, 191, 192, 193, 194, 196, 259, 260, 261, and 262 of subtihsm BPN'. More preferably, the region corresponds to positions 158, 159, 160, 161, 162, 163, 164, 165, 170, 191, 192, 193, 194, 261, and 262 of subtihsm BPN'.
- the region corresponds to positions 158, 159, 160, 161, 162, 163, 164, 192, 193, 194, 261, and 262 of subtihsm BPN'. Most preferably, the region corresponds to positions 160, 161, 162, 163, and 261 of subtihsm BPN'.
- the region preferably corresponds to positions 13, 14, 15, 16, 18, 19, 20, and 21 of subtihsm BPN'. More preferably, the region corresponds to positions 14, 15, 16, 18, 19, 20, and 21 of subtihsm BPN'. Most preferably, the region corresponds to positions 18, 19, 20, and 21 of subtihsm BPN'.
- the region preferably corresponds to positions 2, 3, 4, 5, 6, 7, 12, 17, 40, 41, 43, 67, 86, 87, 89, 206, 209, 214, and 215 of subtihsm BPN'. Most preferably, the region corresponds to positions 2, 3, 4, 5, 17, 40, 41, 43, 67, 86, 87, and 214 of subtihsm BPN'.
- the region preferably corresponds to positions 25, 26, 27, 46, 47, 48, 49, 50, 51, 52, 53, 54, 91, 99, 100, 101, 102, 127, 128, 129, 130, 131, 132, 133, 134, 136, 137, 138, 140, 141, 144, and 145 of subtihsm BPN'.
- the region corresponds to positions 27, 47, 48, 50, 52, 102, 127, 128, 130, 131, 132, 134, 138, and 141 of subtihsm BPN'.
- the region preferably corresponds to positions 9, 10, 22, 23, 24, 62, 63, 143, 146, 154, 155, 156, 157,
- the region corresponds to positions 22, 23, 24, 143, 146, 155.
- Table 2 sets forth non-hmitmg examples of preferred mtramolecularly cross-linked subtihsm proteases wherein, m each example, the position numbers listed indicate the first residue and second residue, respectively, i.e , through which residues the intramolecular crosslink occurs Consistent with the disclosure herein, all residue numbenng corresponds to subtihsm BPN' numbenng.
- the mtramolecularly cross-linked proteases of the present invention may additionally compnse one or more other chemical structures, including (for example) one or more small molecules, polypeptides, and / or polymers covalently attached to any of the residues of the protease (herein referred to as "supplementary moieties"), particularly those residues which do not participate in intramolecular cross-lmkmg.
- supplementary moieties residues which do not participate in intramolecular cross-lmkmg.
- small molecule means a molecule having a molecular weight of less than about 1600, preferably less than about 800, more preferably less than about 400, and most preferably less than about 300.
- polypeptide means a molecule compnsmg two or more amino acid residues).
- the term “polymer” means any molecule which comp ⁇ ses two or more identical (preferably five or more identical) monomer units.
- Supplementary moieties may include polypeptide moieties, polymer moieties, and linking moieties as descnbed in, for example, WO 96/17929, Olsen et al., Novo Nordisk A S, published June 13, 1996; WO 96/40791, Olsen et al.. Novo Nordisk A/S, published December 19, 1996; WO 96/40792, Olsen et al.. Novo Nordisk A/S, published December 19, 1996; WO 97/30148, Bisgard-Frantzen et al..
- protease moieties having a substitution m one or more of the epitope protection positions are prepared by mutating the nucleotide sequences that code for a parent amino acid sequence.
- Such methods are well-known in the art; a non- hmitmg example of one such method is set forth below:
- a phagemid (pSS-5) containing the wild-type subtihsm BPN' gene is transformed into Escherichia coli dut- ung- strain CJ236 and a single stranded uracil-containmg DNA template is produced using the VCSM13 helper phage (Kunkel et al., "Rapid and Efficient Site-Specific Mutagenesis Without Phenotypic Selection", Methods in Enzymology, Vol 154, pp. 367 - 382 (1987), as modified by Yuckenberg et al..
- Fermentation is as follows Bacillus subtilis cells (PG632) containing the protease of interest are grown to mid-log phase m one liter of LB broth containing 10 g/L glucose, and inoculated into a Biostat C fermentor (Braun Biotech, Inc , Allentown, PA) in a total volume of 9 liters
- the fermentation medium contains yeast extract, casem hydrosylate, soluble - partially hydrolyzed starch (Maltnn M-250), antifoam, buffers, and trace minerals (see "Biology of Bacilli. Applications to Industry", Doi, R H and M.
- the fermentation broth is taken through the following steps to obtain pure protease
- the broth is cleared o ⁇ Bacillus subtilis cells by tangential flow against a 0 16 ⁇ m membrane
- the cell-free broth is then concentrated by ultrafiltration with a 8,000 molecular weight cut-off membrane
- the pH is adjusted to 5 5 with concentrated MES buffer (2-(N- morphol ⁇ no)ethanesulfon ⁇ c acid)
- the protease is further purified by cation exchange chromatography with S-sepharose and elution with NaCl gradients See Scopes. R K , "Protein Pu ⁇ fication Pnnciples and Practice", Spnnger-Verlag, New York (1984)
- A/?NA assay (DelMar et al , Analytical Biochemistry, Vol 99, pp 316 - 320 (1979)) is used to determine the active protease concentration for fractions collected dunng gradient elution This assay measures the rate at which »-n ⁇ troan ⁇ lme is released as the protease hydrolyzes the soluble synthetic substrate, succmyl-alanme-alamne-prolme-phenylalanine-p- nitroanihne (sAAPF-/?NA) The rate of production of yellow color from the hydrolysis reaction is measured at 410 nm on a spectrophotometer and is proportional to the active protease moiety concentration In addition, absorbance measurements at 280 nm are used to determine the total protein concentration. The active protease/total-protem ratio gives the protease punty, and is used to identify fractions to be pooled for the stock solution.
- an equal weight of propylene glycol is added to the pooled fractions obtained from the chromatography column.
- the punty of the stock protease solution is checked with SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) and the absolute enzyme concentration is determined via an active site titration method using trypsm inhibitor type II-T: turkey egg white (Sigma Chemical Company, St. Louis, Missouri).
- the protease stock solution is eluted through a Sephadex-G25 (Pharmacia, Piscataway, New Jersey) size exclusion column to remove the propylene glycol and exchange the buffer
- the MES buffer m the enzyme stock solution is exchanged for 0.01 M KH 2 P0 4 solution, pH 5.5.
- Non-hmitmg examples of methods to prepare an mtramolecularly cross-linked protease of the present invention are set forth below wherein, in each example:
- a vanant of subtihsm BPN' with a substitution of leucme for tyrosme at position 217 and a substitution of cysteme for senne at position 78 is prepared.
- the vanant is dialyzed (100 mL at a concentration of approximately 2mg / mL) against 5 liters of 5 mM dithiothreitol (DTT; commercially available from Sigma-Aldnch Co., St. Louis, MO) m pH 5.5 buffer over four hours.
- the va ⁇ ant is transferred to fresh buffer without DTT and dialyzed for about 16 hours.
- the va ⁇ ant concentration is measured by absorbance at 280 nm.
- the thiol concentration is measured (see Deaken et al..
- a vanant of subtihsm BPN' with a substitution of leucme for tyrosme at position 217, a substitution of cysteme for asparagme at position 240, and a substitution of lysine for asparagme at position 118 is prepared. All other lysine residues of the protease are substituted by an ammo acid other than lysine or cysteme.
- the va ⁇ ant is dialyzed (100 mL at a concentration of approximately 2mg / mL) against 5 liters of 5 mM dithiothreitol (DTT; commercially available from Sigma-Aldnch Co., St. Louis, MO) in pH 5.5 buffer over four hours.
- the va ⁇ ant is transferred to fresh buffer without DTT and dialyzed for about 16 hours.
- the va ⁇ ant concentration is measured by absorbance at 280 nm.
- the thiol concentration is measured to ensure free thiol concentration is greater than the protease concentration.
- Succ ⁇ mm ⁇ dyl-4-(N- male ⁇ m ⁇ domethyl)-cyclohexane-l-carboxy(6-am ⁇ docaproate) (commercially available from Pierce Chemical, Rockford, EL) is added at an excess of 1.2 times the free thiol concentration After five minutes, approximately 20 mL of 1M pH 6.8 buffer is added. After an additional 30 minutes, approximately 100 mL of 1M pH 5.5 buffer is added.
- the reaction mixture is then dialyzed against approximately 5 liters of 0.01 M pH 5.5 buffer.
- the mtramolecularly cross- linked protease comprising a covalent linkage between the cysteme of position 240 and the lysine of position 118 is pu ⁇ fied over an ion-exchange column.
- N-(g ⁇ mm ⁇ -male ⁇ m ⁇ dobutyryloxy)succm ⁇ m ⁇ de ester utilized m Example 1 is substituted with any one of the following reagents to form the covalent linkage between the cysteme of position 78 and the ammo terminus: N-( ⁇ /p ztf-male ⁇ m ⁇ doacetoxy)succm ⁇ m ⁇ de ester, N-( ?eta-male ⁇ m ⁇ dopropyloxy)succm ⁇ m ⁇ de ester, or m-maleimidobenzoyl-N-hydroxysuccmimide ester.
- Each of these reagents is commercially available from Pierce Chemical Company, Rockford, IL.
- any reagent containing a maleimide moiety and a succmimidyl ester moiety of similar size can be synthesized and substituted for the N-(gamma- male ⁇ m ⁇ dobutyryloxy)succm ⁇ m ⁇ de ester (see Kalgutar et al consult Journal of Medicinal Chemistry, Vol. 39, pp. 1692 - 1703 (1996) and references therein).
- succm ⁇ m ⁇ dyl-4-(N-male ⁇ m ⁇ domethyl)-cyclohexane- 1 -carboxy(6-am ⁇ docaproate) utilized in Example 2 is substituted with any one of the following reagents to form the covalent linkage between the cysteme of position 240 and the lysine of position 118: succmimidyl 4-(p- male ⁇ m ⁇ dophenyl)-butyrate, sulfosuccimmidyl 4-(p-male ⁇ m ⁇ dophenyl)-butyrate, or N-[kappa- maleimidoundecanoyloxy] sulfosuccmimide ester.
- reagents are commercially available from Pierce Chemical Company, Rockford, IL.
- any reagent containing a maleimide moiety and a succmimidyl ester moiety of similar size can be synthesized and substituted for the N-(g ⁇ mw ⁇ -male ⁇ m ⁇ dobutyryloxy)succm ⁇ m ⁇ de ester (see Kalgutar et al. Journal of Medicinal Chemistry, Vol. 39, pp. 1692 - 1703 (1996) and references therein).
- a vanant of subtihsm BPN' with a substitution of leucme for tyrosme at position 217 and a substitution of cysteme for senne at position 78 is prepared All surface lysine residues of the protease are substituted by an amino acid other than lysme or cysteme.
- the va ⁇ ant is dialyzed (100 mL at a concentration of approximately 2mg / mL) against 5 liters of 5 mM dithiothreitol (DTT; commercially available from Sigma-Aldnch Co., St.
- a vanant of subtihsm BPN' with a substitution of leucme for tyrosme at position 217 and a substitution of cysteme for se ⁇ ne at position 78 is prepared.
- the variant is dialyzed (100 mL at a concentration of approximately 2mg / mL) against 5 liters of 5 mM dithiothreitol (PTT; commercially available from Sigma-Aldnch Co., St. Louis, MO) in pH 5.5 buffer over four hours.
- the va ⁇ ant is transferred to fresh buffer without PTT and dialyzed for about 16 hours.
- the va ⁇ ant concentration is measured by absorbance at 280 nm.
- the thiol concentration is measured to ensure free thiol concentration exceeds the concentration of the protease.
- N- male ⁇ m ⁇ do[4'-az ⁇ do-2'-n ⁇ trophenylammo]butyrate is added at an excess of 1.2 times the free thiol concentration.
- the reaction is exposed to UV light (320 nm - 350 nm) for 10 minutes.
- the reaction is exposed to 10 flashes of a standard camera bulb
- the reaction mixture is then dialyzed against approximately 2 liters 0.01 M pH 5.5 buffer.
- the mtramolecularly cross-linked protease compnsmg a covalent linkage between the cysteme of posihon 78 and the ammo terminus is purified over an ion-exchange column.
- the GMAB utilized in Example 6 is substituted with any one of the following reagents to form the covalent linkage between a lysine substituted at position 78 and the ammo terminus (wherein all other lysine residues of the protease are substituted with another ammo acid): N-5- az ⁇ do-2-mtrobenzoyloxysuccm ⁇ m ⁇ de, N-succm ⁇ m ⁇ dyl-6-(4'-az ⁇ do-2'- n ⁇ trophenylammo)hexanoate, N-hydroxysulfosuccm ⁇ m ⁇ dyl-4-az ⁇ dobenzoate, sulfosucc ⁇ mm ⁇ dyl(4- az ⁇ dosal ⁇ cylam ⁇ do)hexanoate, sulfosuccimmidyl 7-az ⁇ do-4-methylcoumann-3 -acetate, sulfosuccimmidyl 6-(4'-
- a va ⁇ ant of subtihsm BPN' with a substitution of leucme for tyrosme at position 217 and a substitution of cysteme for se ⁇ ne at position 78 and a substitution of cysteme for alanme at position 1 is prepared.
- the va ⁇ ant is dialyzed (100 mL at a concentration of approximately 2mg / mL) against 5 liters of 5 mM dithiothreitol (DTT; commercially available from Sigma-Aldnch Co., St. Louis, MO) in pH 5.5 buffer over four hours.
- the vanant is transferred to fresh buffer without PTT and dialyzed for about 16 hours.
- the vanant concentration is measured by absorbance at 280 nm.
- the thiol concentration is measured to ensure free thiol concentration is greater than twice the protease concentration.
- 10 mL 1M (N-(2-hydroxyethyl)p ⁇ perazme-N'-(2- ethanesulfo c acid)) (HEPES) / NaOH buffer pH 7.0 is added to the protease solution
- Bismaleimidohexane commercially available from Pierce Chemical, Rockford, IL
- the reaction mixture is then dialyzed twice against twenty volumes of 0.01 M pH 5.5 buffer.
- the mtramolecularly cross- linked protease comprising a covalent linkage between the cysteme of position 78 and the cysteme at the amino terminus is purified over an ion-exchange column.
- proteases may be tested for enzymatic activity and immunogenic response using the following methods, both of which are known to one skilled in the art. Other methods well-known in the art may alternatively be used.
- protease activity of an mtramolecularly cross-lmked protease of the present invention may be assayed by methods which are well-known m the art. Two such methods are set forth herein below: Skm Flake Activity Method
- the tape square is then nnsed gently in tap water for fifteen seconds.
- Stevenel Blue Stam (3 mL, commercially available from Sigma Chemical Co., St. Louis, MO) is pipetted into a clean pern dish.
- the nnsed tape square is placed into the stam for three minutes (flake side up) with gentle mixing.
- the tape square is removed from the stam and rinsed consecutively in two beakers of 300 mL distilled water, for fifteen seconds per ⁇ nse.
- the tape square is allowed to air-dry.
- the color intensity between the tape square obtained from the control enzyme and the tape square obtained from the protease is compared visually or by using a chromameter. Relative to the control enzyme tape square, a protease tape square showing less color intensity is indicative of a protease having higher activity.
- the immunogenic potential of the mtramolecularly cross-linked proteases of the present invention may be determined using a methods known in the art or by the Mouse Intranasal Test for lmmunogemcity presented herein below. This test is similar to the assays descnbed in Robinson et al , "Specific Antibody Responses to Subtihsm Carlsberg (Alcalase) m Mice Pevelopment of an Intranasal Exposure Model", Fundamental and Applied Toxicology, Vol. 34, pp. 15 - 24 (1996) and Robmson et al..
- mice Male BPF1 mice (Charles River Laborato ⁇ es, Portage, MI) weighing from about 18 to about 20 grams are utilized in the test. The mice are quarantined one week pnor to dosmg. The mice are housed in cages with wood chip bedding in rooms controlled for humidity (30 - 70%), temperature (67 - 77 °F) and 12 hour light and dark cycles. The mice are fed Punna ® mouse chow (Punna Mills, Richmond, IN) and water ad libitum.
- the potential antigen to be tested is dosed to a group of five mice Pnor to dosmg, each mouse is anesthetized by an mtrapentoneal (l.p.) injection of a mixture of Ketaset (88.8 mg/kg) and Rompun (6.67 mg/kg).
- the anesthetized animal is held m the palm of the hand, back down, and dosed mtranasally with 5 mL protease in buffer solution (0.01 M KH 2 P0 , pH 5.5). While each group receives the same dosage, va ⁇ ous dosages may be tested
- Dosmg solutions are gently placed on the outside of each nostril and inhaled by the mouse Dosmg is repeated on days 3, 10, 17, and 24.
- Serum samples are collected on day 29. Enzyme-specific IgGl antibody m mouse serum is measured by an antigen capture ELISA method Immunogenicities of the mtramolecularly cross-lmked protease may be compared against those of subtihsm BPN' using standard ED 30 values.
- the mtramolecularly cross-lmked proteases herein can be used m any application in which is suitable for the respective parent protease.
- One such example includes cleaning compositions.
- the proteases may further be used in applications which have histo ⁇ cally minimally benefited from the use of proteases. Examples of such applications mclude those m which the mtramolecularly cross-lmked protease necessa ⁇ ly comes in close contact with mammalian skin (especially human skm), such as with the use of personal care compositions.
- the present proteases may be utilized in cleaning compositions including, but not limited to, laundry compositions, hard surface cleansing compositions, light duty cleaning compositions including dish cleansing compositions, and automatic dishwasher detergent compositions.
- the cleaning compositions herein comp ⁇ se an effective amount of one or more proteases of the present invention and a cleaning composition earner.
- an effective amount of protease refers to the quantity of mtramolecularly cross-lmked protease necessary to achieve the proteolytic activity necessary in the specific cleaning composition. Such effective amounts are readily ascertained by one of ordinary skill in the art and is based on many factors, such as the particular protease used, the cleaning application, the specific composition of the cleaning composition, and whether a liquid or dry (e.g , granular, bar) composition is required, and the like.
- the cleaning compositions comp ⁇ se from about 0.0001% to about 10%, more preferably from about 0.001% to about 1%, and most preferably from about 0.01% to about 0.1 % of one or more proteases of the present invention.
- va ⁇ ous cleaning compositions wherein the proteases may be employed are discussed m further detail below
- cleaning compositions further comp ⁇ se a cleaning composition earner compnsmg one or more cleaning composition mate ⁇ als compatible with the protease.
- cleaning composition mate ⁇ al means any matenal selected for the particular type of cleaning composition desired and the form of the product (e g , liquid, granule, bar, spray, stick, paste, gel), which matenals are also compatible with the protease used in the composition.
- the specific selection of cleaning composition mate ⁇ als is readily made by considering the surface matenal to be cleaned, the desired form of the composition for the cleaning condition during use (e g , through the wash detergent use).
- the term "compatible”, as used herein, means the cleaning composition mate ⁇ als do not reduce the proteolytic activity of the protease to such an extent that the protease is not effective as desired dunng normal use situations
- Specific cleaning composition matenals are exemplified in detail hereinafter
- the proteases of the present mvention may be used in a va ⁇ ety of detergent compositions wherein high sudsing and good cleansing is desired.
- the proteases can be used with vanous conventional ingredients to provide fully-formulated hard-surface cleaners, dishwashing compositions, fabnc launde ⁇ ng compositions, and the like.
- Such compositions can be m the form of liquids, granules, bars, and the like.
- Such compositions can be formulated as "concentrated" detergents which contain as much as from about 30% to about 60% by weight of surfactants
- the cleaning compositions herein may optionally, and preferably, contain vanous surfactants (e g , anionic, noniomc, or zwittenonic surfactants). Such surfactants are typically present at levels of from about 5% to about 35% of the compositions.
- vanous surfactants e g , anionic, noniomc, or zwittenonic surfactants.
- Nonhmitmg examples of surfactants useful herein include the conventional C j ] -C ⁇ g alkyl benzene sulfonates and pnmary and random alkyl sulfates, the Ci ⁇ -Cig secondary (2,3) alkyl sulfates of the formulas CH3(CH 2 ) x (CHOS03)-M + )CH 3 and CH3(CH 2 ) y (CHOS0 3 -M + )
- CH2CH3 wherein x and (y+1) are integers of at least about 7, preferably at least about 9, and M is a water-solubihzmg cation, especially sodium, the C ⁇ ⁇ -C ⁇ g alkyl alkoxy sulfates (especially
- EO 1-5 ethoxy sulfates Cjo-Cjg alkyl alkoxy carboxylates (especially the EO 1-5 ethoxycarboxylates), the Ci rj-Ci g alkyl polyglycosides, and their corresponding sulfated polyglycosides, C ⁇ -CJ S a-sulfonated fatty acid esters, Ci 2-C ⁇ alkyl and alkyl phenol alkoxylates (especially ethoxylates and mixed ethoxy/propoxy), Ci 2-C ⁇ g betames and sulfobetaines ("sultames”), Cjo-Cj amme oxides, and the like.
- alkyl alkoxy sulfates AES
- alkyl alkoxy carboxylates AEC
- the use of such surfactants in combination with the amme oxide and / or betame or sultame surfactants is also preferred, depending on the desires of the formulator.
- Other conventional useful surfactants are listed in standard texts. Particularly useful surfactants include the Ci Q -Cig N-methyl glucamides disclosed in U.S. Pat No. 5, 194.639, Connor et al.. issued March 16, 1993.
- a wide va ⁇ ety of other ingredients useful in detergent cleaning compositions can be included in the compositions herein including, for example, other active ingredients, earners, hydrotropes, processing aids, dyes or pigments, and solvents for liquid formulations
- suds boosters such as the Ci g-Ci g alkolamides can be incorporated into the compositions, typically at about 1% to about 10% levels.
- the C10-C14 monoethanol and diethanol amides illustrate a typical class of such suds boosters Use of such suds boosters with high sudsmg adjunct surfactants such as the amme oxides, betames and sultames noted above is also advantageous.
- soluble magnesium salts such as MgCl2,
- MgS04 can be added at levels of, typically, from about 0.1% to about 2%, to provide additional sudsmg.
- the liquid detergent compositions herein may contain water and other solvents as earners.
- Low molecular weight pnmary or secondary alcohols exemplified by methanol, ethanol, propanol, and z ' s ⁇ -propanol are suitable.
- Monohyd ⁇ c alcohols are prefe ⁇ ed for solubihzing surfactants, but polyols such as those containing from about 2 to about 6 carbon atoms and from about 2 to about 6 hydroxy groups (e.g., 1,3-propaned ⁇ ol, ethylene glycol, glyce ⁇ ne, and 1,2- propanediol) can also be used.
- the compositions may contain from about 5% to about 90%, typically from about 10% to about 50% of such earners.
- the detergent compositions herein will preferably be formulated such that dunng use in aqueous cleaning operations, the wash water will have a pH between about 6.8 and about 11. Finished products thus are typically formulated at this range.
- Techniques for controlling pH at recommended usage levels include the use of, for example, buffers, alkalis, and acids. Such techniques are well known to those skilled in the art.
- vanous builders When formulating the hard surface cleaning compositions and fabnc cleaning compositions of the present invention, the formulator may wish to employ vanous builders at levels from about 5% to about 50% by weight.
- Typical builders include the 1-10 micron zeolites, polycarboxylates such as citrate and oxydisuccmates, layered silicates, phosphates, and the like.
- Other conventional builders are listed m standard formula ⁇ es.
- the formulator may wish to employ various additional enzymes, such as cellulases, hpases, amylases, and proteases in such compositions, typically at levels of from about 0.001% to about 1% by weight.
- additional enzymes such as cellulases, hpases, amylases, and proteases
- Vanous detersive and fabric care enzymes are well-known in the laundry detergent art.
- Vanous bleaching compounds such as the percarbonates, perborates and the like, can be used in such compositions, typically at levels from about 1% to about 15% by weight. If desired, such compositions can also contain bleach activators such as tetraacetyl ethylenediamme, nonanoyloxybenzene sulfonate, and the like, which are also known m the art. Usage levels typically range from about 1 % to about 10% by weight.
- Soil release agents especially of the anionic ohgoester type, chelatmg agents, especially the ammophosphonates and ethylenediammedisuccmates, clay soil removal agents, especially ethoxylated tetraethylene pentamine, dispersing agents, especially polyacrylates and polyasparatates, bnghteners, especially anionic bnghteners, suds suppressors, especially sihcones and secondary alcohols, fabric softeners, especially smectite clays, and the like can all be used in such compositions at levels ranging from about 1% to about 35% by weight. Standard formula ⁇ es and published patents contain multiple, detailed descnptions of such conventional mate ⁇ als.
- Enzyme stabilizers may also be used in the cleaning compositions.
- Such enzyme stabilizers include propylene glycol (preferably from about 1% to about 10%), sodium formate (preferably from about 0.1% to about 1%) and calcium formate (preferably from about 0 1% to about 1%)
- hard surface cleaning composition refers to liquid and granular detergent compositions for cleaning hard surfaces such as floors, walls, bathroom tile, and the like
- Hard surface cleaning compositions of the present invention comp ⁇ se an effective amount of one or more proteases of the present invention, preferably from about 0.001%) to about 10%, more preferably from about 0.01%) to about 5%, and more preferably still from about 0.05% to about 1% by weight of protease of the composition.
- such hard surface cleaning compositions typically comp ⁇ se a surfactant and a water-soluble sequestering builder. In certain specialized products such as spray window cleaners, however, the surfactants are sometimes not used since they may produce a filmy and / or streaky residue on the glass surface
- the surfactant component when present, may comprise as little as 0.1% of the compositions herein, but typically the compositions will contain from about 0.25% to about 10%, more preferably from about 1% to about 5% of surfactant
- compositions will contam from about 0.5% to about 50% of a detergency builder, preferably from about 1% to about 10%.
- the pH should be in the range of about 7 to 12.
- Conventional pH adjustment agents such as sodium hydroxide, sodium carbonate, or hydrochlonc acid can be used if adjustment is necessary
- Solvents may be included in the compositions
- Useful solvents mclude, but are not limited to, glycol ethers such as diethyleneglycol monohexyl ether, diethyleneglycol monobutyl ether, ethyleneglycol monobutyl ether, ethyleneglycol monohexyl ether, propyleneglycol monobutyl ether, dipropyleneglycol monobutyl ether, and diols such as 2,2,4-t ⁇ methyl-l,3- pentanediol and 2-ethyl-l,3-hexaned ⁇ ol.
- such solvents are typically present at levels of from about 0.5% to about 15%, more preferably from about 3% to about 11%.
- volatile solvents such as zso-propanol or ethanol can be used in the present compositions to facilitate faster evaporation of the composition from surfaces when the surface is not nnsed after "full strength" application of the composition to the surface.
- volatile solvents are typically present at levels of from about 2% to about 12% in the compositions
- dishwashing compositions compnse one or more va ⁇ ants of the present invention.
- “dishwashing composition” refers to all forms of compositions for cleaning dishes including, but not limited to, granular and liquid forms.
- the present proteases are particularly suited for use in personal care compositions such as, for example, leave-on and ⁇ nse-off hair conditioners, shampoos, leave-on and ⁇ nse-off acne compositions, facial milks and conditioners, shower gels, soaps, foaming and non-foammg facial cleansers, cosmetics, hand, facial, and body lotions, moistu ⁇ zers, patches, and masks, leave-on facial moistu ⁇ zers, cosmetic and cleansing wipes, oral care compositions, catamemals, and contact lens care compositions.
- the present personal care compositions comp ⁇ se one or more proteases of the present invention and a personal care carrier.
- the present proteases are suitable for inclusion in the compositions descnbed in the following references: U.S. Pat. No. 5,641,479, Lmares et al., issued June 24, 1997 (skm cleansers); U.S. Pat. No. 5,599,549, Wivell et al.. issued February 4, 1997 (skm cleansers); U.S. Pat. No. 5,585,104, Ha et al., issued Pecember 17, 1996 (skm cleansers); U.S. Pat. No. 5,540,852, Kefauver et al. issued July 30, 1996 (skm cleansers); U.S. Pat. No 5,510,050, Punbar et al.
- oral cleaning compositions useful for removing protemaceous stams from teeth or dentures.
- oral cleaning compositions refers to dentifrices, toothpastes, toothgels, toothpowders, mouthwashes, mouth sprays, mouth gels, chewing gums, lozenges, sachets, tablets, biogels, prophylaxis pastes, dental treatment solutions, and the like
- the oral cleaning compositions comp ⁇ se from about 0.0001% to about 20% of one or more proteases of the present invention, more preferably from about 0.001% to about 10%, more preferably still from about 0.01% to about 5%, by weight of the composition, and a pharmaceutically-acceptable earner.
- pharmaceutically-acceptable means that drugs, medicaments, or inert ingredients which the term descnbes are suitable for use in contact with the tissues of humans and lower animals without undue toxicity, incompatibility, instability, lr ⁇ tation, allergic response, and the like, commensurate with a reasonable benefit / nsk ratio.
- the pharmaceutically-acceptable oral cleaning carrier components of the oral cleaning components of the oral cleaning compositions will generally comp ⁇ se from about 50% to about 99 99%, preferably from about 65% to about 99.99%, more preferably from about 65% to about 99%, by weight of the composition.
- compositions of the present invention are well known to those skilled in the art.
- composition types, earner components and optional components useful in the oral cleaning compositions are disclosed in the references cited heremabove.
- denture cleaning compositions for cleaning dentures outside of the oral cavity comp ⁇ se one or more proteases of the present invention
- Such denture cleaning compositions comp ⁇ se an effective amount of one or more of the proteases, preferably from about 0.0001% to about 50%, more preferably from about 0.001% to about 35%, more preferably still from about 0.01% to about 20%, by weight of the composition, and a denture cleansing carrier
- Vanous denture cleansing composition formats such as effervescent tablets and the like are well known in the art (see, e.g.. U.S. Pat. No 5,055,305, Young), and are generally appropnate for incorporation of one or more of the proteases for removing protemaceous stams from dentures.
- contact lens cleaning compositions comp ⁇ se one or more proteases of the present invention.
- Such contact lens cleaning compositions comp ⁇ se an effective amount of one or more of the proteases, preferably from about 0.01% to about 50% of one or more of the proteases, more preferably from about 0.01% to about 20%, more preferably still from about 1% to about 5%, by weight of the composition, and a contact lens cleaning carrier.
- Vanous contact lens cleaning composition formats such as tablets, liquids, and the like are well known in the art and are generally appropriate for incorporation of one or more proteases of the present invention for removing protemaceous stams from contact lens
- the above composition is impregnated onto a woven absorbent sheet comp ⁇ sed of cellulose and / or polyester at about 250%, by weight of the absorbent sheet.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Detergent Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA02000835A MXPA02000835A (en) | 1999-07-22 | 2000-07-11 | Intramolecularly crosslinked subtilisin proteases having reduced immunogenicity. |
EP00945316A EP1196546A2 (en) | 1999-07-22 | 2000-07-11 | Intramolecularly cross-linked subtilisin proteases having reduced immunogenicity |
AU59282/00A AU5928200A (en) | 1999-07-22 | 2000-07-11 | Intramolecularly cross-linked subtilisin proteases having reduced immunogenicity |
JP2001512847A JP2003505068A (en) | 1999-07-22 | 2000-07-11 | Intramolecularly crosslinked subtilisin protease with reduced immunogenicity |
BR0012570-9A BR0012570A (en) | 1999-07-22 | 2000-07-11 | Subtilisin proteases intramolecularly cross-linked with reduced immunogenicity |
KR1020027000940A KR20020029371A (en) | 1999-07-22 | 2000-07-11 | Intramolecularly cross-linked subtilisin proteases having reduced immunogenicity |
CA002379718A CA2379718A1 (en) | 1999-07-22 | 2000-07-11 | Intramolecularly cross-linked subtilisin proteases having reduced immunogenicity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14497799P | 1999-07-22 | 1999-07-22 | |
US60/144,977 | 1999-07-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001007576A2 true WO2001007576A2 (en) | 2001-02-01 |
WO2001007576A3 WO2001007576A3 (en) | 2001-06-07 |
Family
ID=22511035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/018853 WO2001007576A2 (en) | 1999-07-22 | 2000-07-11 | Intramolecularly cross-linked subtilisin proteases having reduced immunogenicity |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1196546A2 (en) |
JP (1) | JP2003505068A (en) |
KR (1) | KR20020029371A (en) |
CN (1) | CN1369008A (en) |
AU (1) | AU5928200A (en) |
BR (1) | BR0012570A (en) |
CA (1) | CA2379718A1 (en) |
CZ (1) | CZ2002210A3 (en) |
MX (1) | MXPA02000835A (en) |
WO (1) | WO2001007576A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102335101A (en) * | 2011-02-18 | 2012-02-01 | 苏州润新生物科技有限公司 | Cosmetic with freckle removal function |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2206826A1 (en) * | 1972-02-09 | 1973-08-16 | Schering Ag | Intramolecularly crosslinked insulins - with reduced immunogenicity and prolonged activity |
WO1988008165A1 (en) * | 1987-04-06 | 1988-10-20 | Genex Corporation | Computer based method for protein engineering |
WO1992010755A1 (en) * | 1990-12-05 | 1992-06-25 | Novo Nordisk A/S | Proteins with changed epitopes and methods for the production thereof |
US5543302A (en) * | 1988-05-27 | 1996-08-06 | Solvay Enzymes, Inc. | Proteases of altered stability to autolytic degradation |
-
2000
- 2000-07-11 JP JP2001512847A patent/JP2003505068A/en not_active Withdrawn
- 2000-07-11 CZ CZ2002210A patent/CZ2002210A3/en unknown
- 2000-07-11 BR BR0012570-9A patent/BR0012570A/en not_active IP Right Cessation
- 2000-07-11 KR KR1020027000940A patent/KR20020029371A/en not_active Application Discontinuation
- 2000-07-11 WO PCT/US2000/018853 patent/WO2001007576A2/en not_active Application Discontinuation
- 2000-07-11 MX MXPA02000835A patent/MXPA02000835A/en unknown
- 2000-07-11 CA CA002379718A patent/CA2379718A1/en not_active Abandoned
- 2000-07-11 EP EP00945316A patent/EP1196546A2/en not_active Withdrawn
- 2000-07-11 AU AU59282/00A patent/AU5928200A/en not_active Abandoned
- 2000-07-11 CN CN00810743A patent/CN1369008A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2206826A1 (en) * | 1972-02-09 | 1973-08-16 | Schering Ag | Intramolecularly crosslinked insulins - with reduced immunogenicity and prolonged activity |
WO1988008165A1 (en) * | 1987-04-06 | 1988-10-20 | Genex Corporation | Computer based method for protein engineering |
US5543302A (en) * | 1988-05-27 | 1996-08-06 | Solvay Enzymes, Inc. | Proteases of altered stability to autolytic degradation |
WO1992010755A1 (en) * | 1990-12-05 | 1992-06-25 | Novo Nordisk A/S | Proteins with changed epitopes and methods for the production thereof |
Non-Patent Citations (4)
Title |
---|
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1988 YANG M-L ET AL: "CHEMICAL MODIFICATION OF COBROTOXIN WITH BIFUNCTIONAL REAGENT 1 5 DIFLUORO-2 4-DINITROBENZENE" Database accession no. PREV198987044328 XP002163332 & KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, vol. 4, no. 9, 1988, pages 503-513, ISSN: 0257-5655 * |
GUNDLACH B R ET AL: "Determination of T cell epitopes with random peptide libraries" JOURNAL OF IMMUNOLOGICAL METHODS,NL,ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, vol. 192, no. 1, 10 June 1996 (1996-06-10), pages 149-155, XP004020829 ISSN: 0022-1759 * |
SIEZEN ROLAND J ET AL: "Subtilases: The superfamily of subtilisin-like serine proteases." PROTEIN SCIENCE, vol. 6, no. 3, 1997, pages 501-523, XP000990399 ISSN: 0961-8368 * |
WALSH B AND HOWDEN M: "A method for detection of IgE binding sequences of allergens based on a modification of epitope mapping" JOURNAL OF IMMUNOLOGICAL METHODS,ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM,NL, vol. 121, 1989, pages 275-280-289, XP002112551 ISSN: 0022-1759 * |
Also Published As
Publication number | Publication date |
---|---|
CA2379718A1 (en) | 2001-02-01 |
EP1196546A2 (en) | 2002-04-17 |
AU5928200A (en) | 2001-02-13 |
JP2003505068A (en) | 2003-02-12 |
BR0012570A (en) | 2002-06-04 |
KR20020029371A (en) | 2002-04-18 |
CN1369008A (en) | 2002-09-11 |
CZ2002210A3 (en) | 2002-05-15 |
WO2001007576A3 (en) | 2001-06-07 |
MXPA02000835A (en) | 2002-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3642735B2 (en) | Protease complex | |
JPH09512434A (en) | Subtilisin 309 variants with reduced adsorptivity and increased hydrolyzability | |
WO2001007578A2 (en) | Subtilisin protease variants having amino acid substitutions in defined epitope regions | |
US6566115B1 (en) | Protease conjugates having sterically protected clip sites | |
EP1206526A2 (en) | Subtilisin protease variants having amino acid deletions and substitutions in defined epitope regions | |
US6946128B1 (en) | Protease conjugates having sterically protected epitope regions | |
AU777550B2 (en) | Protease conjugates having sterically protected epitope regions | |
WO2001007576A2 (en) | Intramolecularly cross-linked subtilisin proteases having reduced immunogenicity | |
MXPA00009385A (en) | Protease conjugates | |
CZ20003396A3 (en) | Protease conjugate and personal hygiene preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2379718 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2002-210 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 59282/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/000835 Country of ref document: MX Ref document number: 1020027000940 Country of ref document: KR Ref document number: 008107432 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000945316 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000945316 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027000940 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2002-210 Country of ref document: CZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000945316 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020027000940 Country of ref document: KR |